Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Arrhythmogenic Cardiomyopathy (ACM) Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering.
Arrhythmogenic Cardiomyopathy market landscape report combines primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market. It includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
The report covers several important topics related to the disease and its management. It includes a disease overview, focusing on the pathophysiology and identifying potential druggable targets. The epidemiology section explores the prevalence of the disease, including diagnosed and drug-treated prevalence among the population and key market segments.
For the current treatment, the report outlines the treatment decision tree and highlights the strengths and weaknesses of on-label and off-label treatments. The unmet needs section identifies gaps in treatment or disease management, offering opportunities for improvement.
In the pipeline analysis, the report compares current and emerging therapy strategies in clinical development, assessing their efficacy, safety, and delivery methods, along with their potential to address unmet needs. Finally, the value and access section reviews the evidence required to assess and communicate value to key stakeholders, such as providers, payers, and regulators, and examines competitor strategies in these areas.
Key takeaways from the report:
Arrhythmogenic Cardiomyopathy (ACM) is a rare hereditary cardiac disorder characterized by progressive replacement of myocardial tissue with fibrofatty deposits, leading to life-threatening arrhythmias and cardiac dysfunction.
ACM patients typically receive treatment with beta blockers and anti-arrhythmic drugs to manage symptoms and arrhythmias. However, according to this MarketVue assessment, a striking 50% of patients face treatment failure, necessitating invasive procedures like implantable cardioverter-defibrillators (ICDs), catheter ablation, or even heart transplants which coincide with their own set of challenges.
The urgency for innovative treatments targeting the underlying disease pathophysiology to slow down or halt the progression of the disease, ultimately reducing the risk of life-threatening cardiac events is clear, however, the disease exhibits incomplete penetrance, making risk prediction and patient stratification challenging.
Cardiologist, U.S.: '[There is] the inability to actually prevent the underlying progression since there are no medications that will prevent progression or reduce the cause of arrhythmias, so even if they've got an ICD, they may get shocked from it or have poor quality of life.'
The ACM pipeline remains sparse, with two gene therapies entering early-stage clinical development targeting the PKP2 gene, the most prevalent ACM mutation:
- Rocket Pharmaceuticals' AAVrh74-based gene therapy is in Phase 1
- Lexeo Therapeutics is on track to initiate a Phase 1/2 trial for their AAVrh10-based gene therapy following IND clearance in August 2023
These developments offer new hope to ACM patients, however, given the disease can be caused by genetic mutations outside of PKP2, these treatments would target less than half of diagnosed prevalent patients.
Key companies mentioned:
- Rocket Pharmaceuticals
- Lexeo Therapeutics
- Tenaya Therapeutics
- StrideBio / Ginko Bioworks
- Ginkgo Bioworks
- BioMarin Pharmaceuticals
Key drugs mentioned:
- Beta blockers
- Sotalol (Betapace, Sorine)
- ACE inhibitors
- RP-A601
- TN-401
- STRX-330
- LX2020
- BMN365
- Spironolactone
- Flecainide (Tambocor)
Key Topics Covered:
1. DISEASE OVERVIEW
- A life-threatening, progressive inherited genetic condition impacting cardiac function
- Most common ACM mutations
- Pathogenesis of ACM
2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Prevalence of ACM
- ACM diagnosed prevalence in the United States, 2023
- Prevalence estimates of ACM in the medical literature from 1994 - 2022
- Disease definition
- Diagnosed prevalent cases of PKP2+ ACM by region
- Diagnosed prevalent ACM cases in the US and EU5
- Average prevalence of ACM mutation type
3. DIAGNOSIS AND CURRENT TREATMENT
- Diagnosis overview
- Diagnostic pathway for ARVC patients
- Physician-reported average estimate of ACM patients that receive a diagnosis
- ACM genetic testing dynamics
- KOL estimate of their ACM patients who are PKP2+ with genetic testing
- Physician-reported barriers to genetic testing
- ACM treatment involves pharmacological and device interventions
- Treatment algorithm for management of ACM
- ACM treatment goals
- ACM treatment dynamics
- Current treatment patient share
- Current ACM treatment outcomes
- Upsides and downsides of current interventions used for ACM
- Key treatment dynamics that shape disease management and novel therapy use in ACM
- Must-know ACM market dynamics
- Key treatment dynamics that shape disease management and drug use in ACM
- Important dynamics of ACM market evolution1
4. UNMET NEED
- Overview
- Top unmet needs in ACM
- Physician-reported perspectives on ACM treatment
- ACM disease burden and unmet needs
- Physician-reported disease burden for ACM patients and families
- Most important attributes for new ACM treatment
- Physician perspectives on unmet needs in ACM
5. PIPELINE ANALYSIS
- Summary of the RP-A601 gene therapy trial
- ACM therapies in early pipeline follow similar framework
- Comparison of preclinical ACM gene therapies
- Investigator-sponsored drug-based approaches to ACM
- Estimated proportion of population with positive AAV titers
- Investigator-sponsored ACM trials
- Gene therapy in ACM
- Physician-reported perspectives on ACM treatment and gene therapies
- Attributes that will drive uptake for emerging ACM therapies
- Opportunities and threats for emerging AAV-based ACM gene therapies
- Physician perspectives on ACM gene therapies
6. VALUE & ACCESS
- Overview
- Comparison of gene therapy pricing, U.S.
- Key reimbursement and access considerations for emerging therapies in ACM
- Key insights from the ACM market
- Innovative payer coverage gene therapy insights
7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
- ACM prevalence and population size references
- PKP2 mutation rate methodology
- Mutation rate references
- Pharmaceutical company ACM and PKP2 prevalence estimates
Companies Featured
- Rocket Pharmaceuticals
- Lexeo Therapeutics
- Tenaya Therapeutics
- StrideBio / Ginko Bioworks
- Ginkgo Bioworks
- BioMarin Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/fkz5lz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
